Trial also hits noninferiority mark for adverse cardiac events
PARIS -- Selection of P2Y12 inhibitors based on genetic variants that influence response reduced bleeding events without hurting outcomes in ST-segment elevation MI (STEMI) patients getting stented, the POPular Genetics trial showed.